03 · What You Need to Know
The Ethical Issue Is Context and Comprehension, Not a Mechanical Sequence
Payment Should Not Be Hidden as Though Motivation Were Improper
A common instinct is to conceal payment until late in the recruitment or consent process so prospective participants will supposedly consider the study "for the right reasons."
SACHRP rejects the premise that approved payment must be treated as a secret or surprise. Payment is intended in part to facilitate enrollment, and it cannot do that if prospective participants do not know it exists. SACHRP states that advertising payment can appropriately motivate enrollment when the payment itself is acceptable.
Someone deciding that a study is not worth three hours without compensation is not necessarily making an ethically inferior decision.
But Payment Should Not Dominate the Decision Environment
The opposite strategy creates its own problem.
A recruitment message that says "$1,000 PAYMENT!" in enormous type while barely mentioning a demanding procedure can make the incentive disproportionately salient.
SACHRP recommends that payment information in advertisements be truthful, clear, and appropriately contextualized with study risks and burdens. It says the availability and amount of payment should not be highlighted more than other relevant study information or presented in a way that obscures that information.
Appropriate disclosure
Payment is visible and accurately described alongside enough information about the study for prospective participants to understand what the offer involves.
Overemphasis
The incentive dominates recruitment or consent presentation so strongly that procedures, burdens, risks, or other material information become comparatively obscure.
FDA Requires Payment Information in the Consent Document
For FDA-regulated research, the amount and schedule of payments should be presented to the IRB during initial review. FDA further states that all information concerning payment, including the amount and payment schedule, should be set forth in the informed consent document.
FDA's payment guidance does not prescribe a universal sentence-level sequence in which risks must always precede payment or payment must always precede risks.
That distinction is important. A requirement to disclose information is not the same as a requirement to disclose it at one fixed position.
Consent Is a Process, Not a Race Between Two Paragraphs
Participants need enough information to make an informed and voluntary decision. That includes material information about procedures, risks, burdens, possible benefits where relevant, alternatives where applicable, voluntariness, and payment conditions.
Focusing excessively on whether the payment paragraph appears before or after the risk paragraph can distract from whether participants actually understand either one.
SACHRP's undue-influence analysis focuses on whether incentives are likely to inhibit adequate consideration and reflection about important study features such as risks, burdens, and discomforts or impair understanding.
The ethical target is therefore adequate consideration, not ritual sequencing.
The First Information Participants See Still Matters
Saying that there is no universal order does not mean order is irrelevant.
Recruitment advertisements, social-media posts, emails, participant-pool listings, and landing pages often provide the first framing of the study. If that framing consists almost entirely of the incentive, participants may approach everything that follows through the lens of the reward.
SACHRP calls advertising the first step in the consent process and recommends contextualizing payment with study risks and burdens.
The practical implication is not "never mention payment first." It is "do not let payment become the only meaningful thing participants learn first."
Key Information Can Integrate Payment With the Study Decision
For research governed by the revised Common Rule, informed consent must begin with a concise and focused presentation of key information most likely to help a reasonable person understand why someone might or might not want to participate.
What qualifies as key information depends on the study. In some research, the time commitment, major procedures, important risks, and payment arrangement may all materially affect the decision.
SACHRP specifically notes that the Common Rule's key-information approach may help support adequate decision-making when incentive payments are involved.
Rather than forcing payment and risk into separate camps, researchers can present them as parts of the same practical decision.
A High Incentive May Justify Greater Attention to Presentation
The larger or more salient an incentive becomes, the more carefully researchers should consider whether participants are attending to the rest of the study information.
OHRP states that payment should not be so high that it compromises a prospective participant's examination and evaluation of research risks or affects voluntariness. SACHRP similarly focuses on whether an incentive inhibits adequate reflection about risks, burdens, and discomforts.
This does not produce a rule saying "risks must come first." It may instead support clearer key information, balanced recruitment materials, comprehension checks, additional discussion, or other safeguards appropriate to the study.
Payment Amount and Payment Conditions Both Matter
Telling participants "$200" without explaining when it is paid or what happens after withdrawal is incomplete.
FDA requires both amount and schedule in the informed consent document. Payment conditions may also affect whether someone considers participation worthwhile, particularly in longitudinal studies.
A participant should understand whether payment accrues by visit, whether expenses are reimbursed separately, whether a portion is a completion incentive, and what happens if participation ends early.
These distinctions connect disclosure order to payment after withdrawal and prorated participant payment.
Risk Information Should Not Be Minimized Because Payment Is Attractive
Payment cannot compensate for weak risk disclosure.
OHRP emphasizes that informed consent must be voluntary and that incentives should not cloud appreciation of research risks or potential benefits. SACHRP likewise emphasizes clear and complete information and adequate comprehension.
If a researcher worries that explaining the risks clearly will discourage enrollment, that is not a reason to delay, dilute, or obscure the risk information.
Watch Out
Do not manipulate disclosure order primarily to secure a "yes." The purpose of recruitment and consent information is to support an informed decision, including a well-informed decision not to participate.
Payment Can Be Mentioned in Recruitment Materials
SACHRP states that there is no reason approved payment should be concealed from advertisements. Its concern is appropriate contextualization, not prohibition.
This means researchers need not recruit participants with vague phrases such as "compensation may be available" when the approved amount can appropriately be stated more clearly.
At the same time, recruitment material is not the entire consent process. A short advertisement cannot carry every detail of the study, so its design should invite informed consideration rather than substitute the incentive for the study description.
Different Studies May Justify Different Presentation
A minimal-risk online survey and an invasive clinical study do not necessarily need identical recruitment and consent presentation.
Likewise, a modest reimbursement for transportation differs from a substantial recruitment incentive. The more consequential the study's risks and the more salient the incentive, the stronger the case for ensuring that participants encounter the information in a balanced and comprehensible form.
This contextual approach is consistent with OHRP's broader position that undue influence depends on the participant population, incentive, and circumstances of the offer rather than a bright-line rule.
Do Not Confuse Reimbursement With a Recruitment Incentive
A statement that travel expenses will be reimbursed may matter to whether someone can afford to participate, but it does not necessarily create the same concern as a large net incentive.
SACHRP distinguishes reimbursement and fair compensation from incentive payments and argues that the latter deserve greater attention for possible undue influence.
Researchers deciding how prominently to present payment should therefore first understand what type of payment they are disclosing.
